CULLINAN THERAPEUTICS INC (CGEM) Stock Analyst Earnings Estimates
NASDAQ:CGEM - Nasdaq - US2300311063 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 18.94M | 141.16M -100.00% | 8.556M | 33.956M 296.87% | 79.287M 133.50% | 59.186M -25.35% | 242.98M 310.54% | 510M 109.89% | 1.339B 162.55% | |||||
| EBITDA YoY % growth | -22.2M -52.58% | -60.28M -171.53% | -67.9M -12.64% | 147.98M -91.53% | -195.671M -46.36% | -198.123M -4.09% | -219.737M -10.91% | -208.843M 4.96% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -22.27M -52.64% | -60.34M -170.95% | -67.95M -12.61% | 148.39M -91.52% | -196.334M -46.50% | -197.881M -3.79% | -216.184M -9.25% | -217.283M -0.51% | -258.853M -19.13% | -255.631M 1.24% | -132.76M 48.07% | 65.582M 149.40% | 1.297B 1,877.68% | |
| Operating Margin | N/A | N/A | -358.76% | 105.12% | N/A | N/A | -2,526.70% | -639.90% | -326.48% | -431.91% | -54.64% | 12.86% | 96.86% | |
| EPS YoY % growth | N/A | N/A | -1.50 9.41% | 2.38 258.00% | -4.17 -255.70% | -3.12 15.57% | -3.15 -1.10% | -3.06 2.94% | -2.26 25.93% | -2.88 -27.03% | -2.12 26.12% | 0.30 114.08% | 15.96 5,235.83% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.77 -43.12% | -0.83 3.78% | -0.81 -7.78% | -0.83 -20.11% | -0.81 -5.36% | -0.64 22.34% | -0.64 20.50% | -0.69 16.31% | -0.74 8.56% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | -54.55M -20.75% | -55.886M -30.23% | -56.977M -14.24% | -58.099M -19.48% | -59.242M -8.60% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -53.307M -17.20% | -55.298M -28.63% | -57.029M -14.00% | -59.136M -21.04% | -59.688M -11.97% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.69 24.18% | -0.82 | 0.13 | 16.07% |
| Q2 2024 Q2Q % growth | -0.75 8.54% | -0.74 | -0.01 | -1.34% |
| Q1 2024 Q2Q % growth | -0.86 39.44% | -1.01 | 0.15 | 14.81% |
| Q4 2023 Q2Q % growth | -0.54 8.47% | -0.98 | 0.44 | 44.93% |
| Q3 2023 Q2Q % growth | -0.91 -68.52% | -0.94 | 0.03 | 3.20% |
| Q2 2023 Q2Q % growth | -0.82 -121.75% | -0.99 | 0.17 | 17.12% |
| Q1 2023 Q2Q % growth | -1.42 -425.93% | -1.00 | -0.42 | -42.06% |
| Q4 2022 Q2Q % growth | -0.59 20.27% | -0.68 | 0.09 | 13.02% |
| Q3 2022 Q2Q % growth | -0.54 -35.00% | -0.99 | 0.45 | 45.23% |
| Q2 2022 Q2Q % growth | 3.77 1,147.22% | 5.53 | -1.76 | -31.76% |
| Q1 2022 Q2Q % growth | -0.27 | -0.62 | 0.35 | 56.61% |
| Q4 2021 Q2Q % growth | -0.74 74.13% | -0.48 | -0.26 | -53.27% |
| Q3 2021 Q2Q % growth | -0.40 | -0.43 | 0.03 | 7.36% |
| Q2 2021 Q2Q % growth | -0.36 | -0.42 | 0.06 | 14.95% |
| Q1 2021 Q2Q % growth | 0.00 | 0.07 | -0.07 | -100.00% |
| Q4 2020 Q2Q % growth | -2.86 | -0.39 | -2.47 | -628.29% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2022 Q2Q % growth | 280.5M | -280.5M | -100.00% | |
| Q1 2022 Q2Q % growth | -100.00% | % | ||
| Q1 2021 Q2Q % growth | 18.94M | 19.38M | -440K | -2.27% |
| Q4 2020 Q2Q % growth | 9.18M | -9.18M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 6.07% | 9.02% | 1.74% | 5.82% |
| Revenue | N/A | N/A | N/A | N/A |